Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amiselimod in mild to moderate ulcerative colitis
NCT04857112Phase 2Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Sep 2021
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 2 trial of amiselimod in ulcerative colitis (UC), sponsored by Valeant Pharmaceuticals. Started Sep 2021; status: completed.
02
Drugs
amiselimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04857112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04857112.